Rutgers Gets $6 Million to Develop Revolutionary Ways to Manufacture Prescription Medicines

Janssen Pharmaceutical has furthered its strategic partnership with the Rutgers University School of Engineering by providing $6 million to expand research that will help pharmaceutical companies develop new ways to manufacture prescription medicines.

The funds from Janssen, a unit of New Brunswick-based Johnson & Johnson, one of the world’s largest health care companies, will increase research and development at the Rutgers Engineering Research Center for Structured Organic Particulate Systems over the next several years.

The center is helping Janssen and other pharmaceutical companies implement a technique called continuous manufacturing that is expected to revolutionize the industry in the coming years and enable companies to deliver the latest medications to patients more quickly, with higher quality and potentially even at lower cost.

Continuous manufacturing, one of the more significant advances in pharmaceutical manufacturing in decades, is important because it is more efficient and less expensive than conventional methods to produce tablets and can help companies introduce new products faster while improving quality control.

“Continuous manufacturing represents the future of advanced pharmaceutical manufacturing,” said Fernando J. Muzzio, professor II, Department of Chemical and Biochemical Engineering. “With this latest funding, our center is now better positioned than ever to serve the scientific community, pharmaceutical companies and the regulatory agencies as the industry moves to this new process over the next decade.”

Vaccine Rollout Will be Hindered by Supply Chain Disruption

Catalent Signs Agreement to Manufacture Lead COVID-19 Vaccine Candidate

Johnson & Johnson Announces Definitive Agreement to Collaborate With Google to Advance Surgical Robotics